Abstract 354P
Background
Colorectal cancer (CRC) presents among leading causes of death and oligometastases presents a dilemma in treatment options. If treated, CRC with oligometastases can present improved survival. Our study aims to evaluate predictive factors associated with survival when treated with stereotactic body radiation therapy (SBRT).
Methods
A total of 125 metastases in 50 patients were treated with SBRT. Oligometastases was defined as up to 5 lesions in lung in proven primary histopathology of CRC. Survival outcomes in terms of local control (LC), progression free survival (PFS), and overall survival (OS) were assessed along with association of various predictive factors associated with survival outcomes.
Results
Among the 50 patients, Lung was the most common site of metastases (52.5%), followed by liver (34%). Thirty patients had received prior systemic therapy in form of chemotherapy. Median follow-up time was 24 months (6-84 months). The LC rates at 1, 3 and 5 years were 96%, 72% and 69%, respectively. The first site of failure was local only in 20%, distant only in 34%, and local and distant in 16% of the patients. Median PFS was 9.8 months. The overall survival at 1, 3 and 5 years was 87.2%, 62.3%, and 41.4%, respectively. On assessment of predictive factors, metastases more than 3 cm (p =0.012), presence of non-lung metastases (p < 0.001) and progression of treated metastases (p = 0.021) predicted for worse overall survival.Multiple lung metastases and synchronous oligometastatic disease were significantly associated with worse PFS and worse metastases-free survival. On toxicity assessment, no Grade 3 toxicities were found in the cohort.
Conclusions
Stereotactic body radiation therapy presents longer survival in oligometastases in CRC and is a proven treatment modality. Treatment and control of oligometastases predicts for improved overall survival. Further prospective cohorts would better evaluate effective fractionation for patients with oligometastatic CRC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
511P - Phase II trial of carboplatin, nab-paclitaxel and bevacizumab for advanced non-squamous non-small cell lung cancer (CARNAVAL study; TORG1424/OLCSG1402)
Presenter: Toshio Kubo
Session: Poster display session
Resources:
Abstract
485P - A real-world experience of first-line afatinib in Korean patients with EGFR-mutant non-small cell lung cancer
Presenter: Seong Hoon Yoon
Session: Poster display session
Resources:
Abstract
522P - Weekly nab-PTX and weekly PTX for relapsed small cell lung cancer
Presenter: Hajime Oi
Session: Poster display session
Resources:
Abstract
512P - A phase I and extension study of S-1 and carboplatin for previously untreated patients aged 75 years or more with advanced non-small cell lung cancer
Presenter: Hisao Imai
Session: Poster display session
Resources:
Abstract
497P - Real-word efficacy of osimertinib in patients with metastatic EGFRm NSCLC: An interim analysis from a multi-center study in China
Presenter: Xiangyun Ye
Session: Poster display session
Resources:
Abstract
507P - Immune checkpoint inhibitors for patients acquired resistance to tyrosine kinase inhibitors with EGFR mutated non-small cell lung cancer: A multicenter retrospective study
Presenter: Takeshi Uenami
Session: Poster display session
Resources:
Abstract
516P - Clinical outcomes in elderly patients with advanced non-small cell lung cancer: A prospective multicenter study of the National Hospital Organization in Japan
Presenter: Masahiro Shimada
Session: Poster display session
Resources:
Abstract
486P - Phase II study of low-dose afatinib maintenance treatment for patients with EGFR-mutated non-small cell lung cancer (NJLCG1601)
Presenter: Mami Morita
Session: Poster display session
Resources:
Abstract
515P - Polypharmacy as a prognostic factor in elderly patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors
Presenter: Taiki Hakozaki
Session: Poster display session
Resources:
Abstract
518P - Real world prospective clinical impact of finding actionable genomic alterations by plasma cell-free DNA next generation sequencing in advanced non-small cell lung cancer
Presenter: Beung chul Ahn
Session: Poster display session
Resources:
Abstract